These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 10037179)

  • 1. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
    Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
    Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
    Reid JM; Stevens DC; Rubin J; Ames MM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition and pharmacokinetics of temozolomide in rat.
    Reyderman L; Statkevich P; Thonoor CM; Patrick J; Batra VK; Wirth M
    Xenobiotica; 2004 May; 34(5):487-500. PubMed ID: 15370964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
    Aoki T; Nishikawa R; Mizutani T; Nojima K; Mishima K; Adachi J; Matsutani M
    Int J Clin Oncol; 2007 Oct; 12(5):341-9. PubMed ID: 17929115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
    Kim HK; Lin CC; Parker D; Veals J; Lim J; Likhari P; Statkevich P; Marco A; Nomeir AA
    J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):225-33. PubMed ID: 9448080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
    Beale P; Judson I; Moore S; Statkevich P; Marco A; Cutler DL; Reidenberg P; Brada M
    Cancer Chemother Pharmacol; 1999; 44(5):389-94. PubMed ID: 10501912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis and stability study of temozolomide using capillary electrophoresis.
    Andrasi M; Bustos R; Gaspar A; Gomez FA; Klekner A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jul; 878(21):1801-8. PubMed ID: 20627825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
    Kirstein MN; Panetta JC; Gajjar A; Nair G; Iacono LC; Freeman BB; Stewart CF
    Cancer Chemother Pharmacol; 2005 May; 55(5):433-8. PubMed ID: 15818507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
    Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
    Riccardi A; Mazzarella G; Cefalo G; Garrè ML; Massimino M; Barone C; Sandri A; Ridola V; Ruggiero A; Mastrangelo S; Lazzareschi I; Caldarelli M; Maira G; Madon E; Riccardi R
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):459-64. PubMed ID: 13680160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
    Ma J; Pulfer S; Li S; Chu J; Reed K; Gallo JM
    Cancer Res; 2001 Jul; 61(14):5491-8. PubMed ID: 11454697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
    Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
    Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
    Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 1st communication: absorption and excretion in rats after a single administration of 14C-NS-49.
    Mukai H; Watanabe S; Morino A
    Arzneimittelforschung; 1999 May; 49(5):434-40. PubMed ID: 10367106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
    Chowdhury SK; Laudicina D; Blumenkrantz N; Wirth M; Alton KB
    J Pharm Biomed Anal; 1999 Apr; 19(5):659-68. PubMed ID: 10698531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.